The Efficacy and Safety of Biologics (Belimumab/ Telitacicept) Induction Therapy in Proliferative Lupus Nephritis Patients for 6 Months Compared With Mycophenolate Mofetil Treatment

NCT07340463

Status	RECRUITING
Phase	Phase 2
Sponsor	Nanjing University School of Medicine
Enrollment	50 participants

Key Eligibility Criteria

Inclusion (3)

- Signed written informed consent form. 2.Age 14-65 years (inclusive), any gender. 3.Meets the American College of Rheumatology (ACR) SLE diagnostic criteria (1997).
- All patients have biopsy-confirmed class III/IV ± V LN within the past six months.
- SLE-DAI score \> 6. 6.Urine protein quantification \> 1.0 g/d.

Exclusion (9)

- Estimated glomerular filtration rate (eGFR) e45 ml/min/1.73 m². 2.Patients who have received renal replacement therapy, plasma exchange, immunoadsorption, or high-dose intravenous immunoglobulin (100g) within the past 2 months.
- Patients with concomitant critical organ damage or lupus crisis (e.g., pulmonary hemorrhage, encephalopathy, heart failure) deemed unsuitable for clinical trial participation by the investigator.
- Hematological abnormalities: White blood cells \<3000/Ľ absolute neutrophil count \<1500/Ľ or lymphocytes \<800/Ľ platelet count \<50,000/Ľ(unless due to SLE activity).
- Liver function abnormalities: ALT, AST, or bilirubin levels exceeding 2 times the upper limit of normal.
- Known allergy or contraindication to any component of belimumab and/or telitacicept.

... and 4 more (see full listing online)

Locations (1 total)

Clinical Research Ethics Committee of the General Hospital of Eastern Theater Command of the People's Liberation Army, Nanjing, Jiangsu, China